July 14, 2020
Roche and its group firm Chugai Pharmaceutical said on July 13 that their immuno-oncology agent Tecentriq (atezolizumab) failed to extend progression-free survival (PFS), one of two primary endpoints, in a PIII study for the frontline treatment of advanced ovarian cancer...read more